| Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group S Kelly, N Jahanshad, A Zalesky, P Kochunov, I Agartz, C Alloza, ... Molecular psychiatry 23 (5), 1261-1269, 2018 | 559 | 2018 |
| Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials CA Bousman, K Arandjelovic, SG Mancuso, HA Eyre, BW Dunlop Pharmacogenomics 20 (01), 37-47, 2019 | 165 | 2019 |
| Accelerated gray and white matter deterioration with age in schizophrenia VL Cropley, P Klauser, RK Lenroot, J Bruggemann, S Sundram, ... American Journal of Psychiatry 174 (3), 286-295, 2017 | 159 | 2017 |
| Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study J Sarris, C Stough, CA Bousman, ZT Wahid, G Murray, R Teschke, ... Journal of clinical psychopharmacology 33 (5), 643-648, 2013 | 157 | 2013 |
| Commercial pharmacogenetic-based decision-support tools in psychiatry CA Bousman, M Hopwood The Lancet Psychiatry 3 (6), 585-590, 2016 | 134 | 2016 |
| An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels J De Leon, G Schoretsanitis, RL Smith, E Molden, A Solismaa, N Seppälä, ... Pharmacopsychiatry 55 (02), 73-86, 2022 | 126 | 2022 |
| White matter disruptions in schizophrenia are spatially widespread and topologically converge on brain network hubs P Klauser, ST Baker, VL Cropley, C Bousman, A Fornito, L Cocchi, ... Schizophrenia bulletin 43 (2), 425-435, 2017 | 122 | 2017 |
| Review and consensus on pharmacogenomic testing in psychiatry CA Bousman, SA Bengesser, KJ Aitchison, AT Amare, H Aschauer, ... Pharmacopsychiatry 54 (01), 5-17, 2021 | 118 | 2021 |
| Predictors of substance use among homeless youth in San Diego CA Bousman, EJ Blumberg, AM Shillington, MF Hovell, M Ji, S Lehman, ... Addictive behaviors 30 (6), 1100-1110, 2005 | 116 | 2005 |
| Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: convergent pathway analysis findings from two independent samples CA Bousman, G Chana, SJ Glatt, SD Chandler, GR Lucero, E Tatro, ... American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 153 …, 2010 | 113 | 2010 |
| Evidence for network-based cortical thickness reductions in schizophrenia CMJ Wannan, VL Cropley, MM Chakravarty, C Bousman, EP Ganella, ... American Journal of Psychiatry 176 (7), 552-563, 2019 | 103 | 2019 |
| Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools CA Bousman, BW Dunlop The pharmacogenomics journal 18 (5), 613-622, 2018 | 101 | 2018 |
| ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression AB Singh, CA Bousman, CH Ng, K Byron, M Berk Translational psychiatry 2 (11), e198-e198, 2012 | 100 | 2012 |
| Systematic review and critical appraisal of child abuse measurement instruments SM Saini, CR Hoffmann, C Pantelis, IP Everall, CA Bousman Psychiatry research 272, 106-113, 2019 | 94 | 2019 |
| Genetic association studies of methamphetamine use disorders: a systematic review and synthesis CA Bousman, SJ Glatt, IP Everall, MT Tsuang American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 150 …, 2009 | 93 | 2009 |
| Antidepressant prescribing in the precision medicine era: a prescriber’s primer on pharmacogenetic tools CA Bousman, M Forbes, M Jayaram, H Eyre, CF Reynolds, M Berk, ... BMC psychiatry 17, 1-7, 2017 | 83 | 2017 |
| Neuregulin-1 and schizophrenia in the genome-wide association study era MS Mostaid, D Lloyd, B Liberg, S Sundram, A Pereira, C Pantelis, T Karl, ... Neuroscience & Biobehavioral Reviews 68, 387-409, 2016 | 83 | 2016 |
| Towards the integration of pharmacogenetics in psychiatry: a minimum, evidence-based genetic testing panel C Bousman, A Al Maruf, DJ Müller Current opinion in psychiatry 32 (1), 7-15, 2019 | 81 | 2019 |
| Early origins of mental disorder-risk factors in the perinatal and infant period L Newman, F Judd, CA Olsson, D Castle, C Bousman, P Sheehan, ... BMC psychiatry 16 (1), 1-8, 2016 | 81 | 2016 |
| The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes R Wells, V Swaminathan, S Sundram, D Weinberg, J Bruggemann, ... npj Schizophrenia 1 (1), 1-8, 2015 | 75 | 2015 |
Christos PantelisProfessor of Neuropsychiatry, University of MelbourneVerified email at unimelb.edu.au
